Catalyst Crew Technologies Corp. (OTC: CCTC) announced on March 26, 2026, the ongoing development of CardioAI, an artificial intelligence-enabled module designed to support cardiovascular risk assessment and predictive modeling. The platform is intended to assist healthcare providers in analyzing cardiovascular health data and identifying potential clinical risks through AI-driven analytics.
CardioAI's proposed capabilities include heart failure risk modeling, arrhythmia detection algorithms, coronary artery disease risk scoring, and AI-assisted analysis of electrocardiograms and echocardiograms. The platform is being developed to integrate multiple data inputs, such as diagnostic imaging, clinical parameters, laboratory results, and patient demographic information, to generate structured outputs that support clinical review and care coordination.
As part of Catalyst Crew's broader AI healthcare platform, CardioAI is expected to function as a specialized module within the company's digital health ecosystem. Management believes that modular AI systems like CardioAI may support scalable deployment across telehealth services, remote patient monitoring, and technology-enabled healthcare delivery environments. The company intends to integrate CardioAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform.
Catalyst Crew Technologies is prioritizing market development in Latin America, where the company believes AI-enabled healthcare technologies can help expand access to cardiovascular screening, support early risk identification, and improve healthcare system efficiency. The region represents a significant opportunity for digital health innovation as healthcare systems increasingly seek scalable solutions to improve diagnostic capabilities and support remote patient care.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated: “Cardiovascular disease remains one of the leading global health challenges, and we believe artificial intelligence can play an important role in supporting earlier detection and more informed clinical decision-making. CardioAI reflects our broader strategy of developing modular, scalable healthcare technologies designed to integrate into real-world healthcare delivery systems.”
The company intends to continue developing and refining CardioAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. For more information, visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This announcement underscores the growing trend of applying artificial intelligence to cardiovascular care, particularly in emerging markets where access to specialized diagnostics is limited. If successfully deployed, CardioAI could help reduce the burden of cardiovascular disease by enabling earlier detection and more efficient care coordination, potentially improving outcomes for patients in underserved regions.
